Can We Manage Presymptomatic TTR V142I Related Risk?
- PMID: 35115087
- DOI: 10.1016/j.jchf.2021.10.009
Can We Manage Presymptomatic TTR V142I Related Risk?
Keywords: DNA-based screening; TTR V122I; TTR V142I; hs-TnI; myocardial injury; transthyretin cardiac amyloidosis.
Conflict of interest statement
Funding Support and Author Disclosures The authors are co-investigators in transthyretin cardiac amyloidosis (ATTR-CA) research funded by Pfizer. Dr Miller is a consultant and has grant support from Eidos and Alnylam.
Comment on
-
Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.JACC Heart Fail. 2022 Feb;10(2):129-138. doi: 10.1016/j.jchf.2021.09.006. Epub 2021 Dec 8. JACC Heart Fail. 2022. PMID: 35115086
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous